A review of response in neoadjuvant therapy for exocrine pancreatic cancer

Dominic J. Vitello, David J. Bentrem*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Despite overall advances in cancer therapy, patients with pancreatic ductal adenocarcinoma continue to have a poor prognosis. While adjuvant therapy is still considered standard, there is mounting evidence that neoadjuvant therapy confers similar benefits in patients with locally advanced disease. The primary measures of response are radiographic, biochemical, margin status, and pathologic. Given overall low response rates and the need for new treatment strategies, standard metrics remain important to the investigation of new systemic agents.

Original languageEnglish (US)
Pages (from-to)1449-1459
Number of pages11
JournalJournal of surgical oncology
Issue number6
StatePublished - May 1 2021


  • exocrine pancreatic cancer
  • neoadjuvant therapy
  • pancreatic ductal adenocarcinoma
  • response

ASJC Scopus subject areas

  • Surgery
  • Oncology


Dive into the research topics of 'A review of response in neoadjuvant therapy for exocrine pancreatic cancer'. Together they form a unique fingerprint.

Cite this